Objective: To compare the non-motor symptom assessment scale (NMSS) score between Leucine-rich repeat kinase 2 (LRRK2) mutation carriers with Parkinson disease (PD) and matched controls with PD.

Background: The autosomal dominant LRRK2 mutation is the most common genetic etiology for late onset Parkinson disease (PD).  Motor and non-motor symptoms were generally similar between LRRK2 G2019S positive PD and LRRK2 negative PD in prior studies.

Methods: 251 subjects began and 231 completed LRRK2 G2019S mutation testing and non-motor symptom assessment scale (NMSS).  We compared NMSS between 9 LRRK2 positive subjects and 18 LRRK2 negative controls matched for age, PD duration, education, and gender.   We utilized the Mann-Whitney U Test to compare the distribution of NMSS scores between LRRK2+ subjects and matched controls. 

Results: Of 231 subjects with PD (23.4% of whom were Ashkenazi Jewish), 9 were LRRK2 G2019S positive.  Average (standard deviation) NMSS score was 69.22 (43.99) in the 9 LRRK2 positive subjects versus 55.83 (36.48) in 18 matched controls.  We found no significant difference in NMSS score between LRRK2 positive subjects and matched controls (p=0.403).   

Conclusions: There was no significant difference in NMSS score between LRRK2 positive PD and matched LRRK2 negative PD controls.  This confirms the similarity in non-motor phenotype reported in the literature between LRRK2 and sporadic PD.  Further study is warranted with larger samples of LRRK2 subjects in order to better define the non-motor symptoms in G2019S LRRK2 positive PD.

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/comparison-of-the-non-motor-symptom-assessment-scale-between-lrrk2-g2019s-positive-versus-matched-control-parkinson-disease/